What is really known about psychological alterations produced by psychiatric drugs?

International Journal of Risk and Safety in Medicine

Volumn 12, Issue 1, 1999, Pages 37-47

  Jacobs, David ^a   Cohen, David ^b  

^a Center for the Study of Psychiatry and Psychology Southwest   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; DROPERIDOL; DRUG; FLUOXETINE; IMIPRAMINE; LITHIUM; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

AKATHISIA; ANXIETY NEUROSIS; ARTICLE; COMPULSION; DRUG EFFECT; DRUG INDUCED DISEASE; HUMAN; MEDICAL RESEARCH; MENTAL DISEASE; METHODOLOGY; RANDOMIZATION; SYMPTOMATOLOGY;

EID: 0033020364     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. P.R. Breggin, Brain Disabling Treatments in Psychiatry, Springer, New York, 1997.
2. P.R. Breggin, Electroshock: Its Brain-Disabling Effects, Springer, New York, 1979.
3. I. Chalmers, Unbiased, relevant, and reliable assessments in health care, Brit. Med. J. 317 (1998), 1167-1168.
4. D. Cohen, A critique of the use of neuroleptic drugs in psychiatry, in: From Placebo to Panacea: Putting Psychiatric Drugs to the Test, S. Fisher and R.P. Greenberg, eds, Wiley, New York, 1997, pp. 173-228.
5. J.B. Cohn and C. Wilcox, A comparison of fluoxetine, imipramine, and placebo inpatients with major depressive disorder, J. Clin. Psychiatr. 46 (1985), 26-31.
6. J.O. Cole, Behavioral toxicity, in: Drugs and Behavior, L. Uhr and J.G. Miller, eds, Wiley, New York, London, 1960, pp. 166-183.
7. I. Elkin, M.T. Shea, J.T. Watkins, S.D. Imber et al., National Institute of Mental Health: Treatment of Depression; Collaborative Research Program, Arch. Gen. Psychiatr. 46 (1989), 971-982.
8. Freyhan F.A. Psychopharmacology and the controversial clinician, in: Drugs and Behavior, L. Uhr and J.G. Miller, eds, Wiley, New York, London, 1960, pp. 184-198.
9. S. Golombok, M. Parmala and M. Lader, Cognitive impairment in long-term benzodiazepine users, Psychol. Med. 18 (1988), 365-374.
10. L.F. Gram, Fluoxetine, New Eng. J. Med. 331 (1994), 1354-1361.
11. D. Healy and G. Farquhar, Immediate effects of droperidol, Hum. Psychopharmacol. 13 (1998), 113-120.
12. A. Herxheimer, Side effects: freedom of information and the communication of doubt, in: Side Effects of Drugs Annual 1995, J.K. Aronson and C.J. Van Boxtel, eds, Elsevier Science, Amsterdam, Lausanne and New York, 1996, pp. xix-xxvii.
13. R. Hoehn-Saric, J.R. Lipsey and D.A. McLeod, Apathy and indifference in patients on fluvoxamine and fluoxetine, J. Clin. Psychopharmacol. 10 (1990), 343-345.
14. P. Irwin and J. Singer, A guide for clinical studies with potential antipsychotic or antidepressant medications, Clin. Res. Pract. & Drug Regul. Affairs 6 (1988), 293-411.
15. L.L. Judd, B. Hubbard, D.S. Janowsky, L.Y. Huey and P.A. Attewell, The effect of lithium carbonate on affect, mood and personality of normal subjects, Arch. Gen. Psychiatr. 34 (1977), 346-351.
16. L.L. Judd and B.R. Hubbard, The effects of lithium carbonateon sodium phenobarbital induced high in normal subjects, Psychopharmacol. Communicat. 1 (1975), 631-639.
17. R.A. King, M.A. Riddle, P.B. Chappell et al., Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment, J. Amer. Acad. Child and Adolesc. Psychiatr. 30 (1991), 179-186.
18. J.F. Lipinski, Jr., G. Mallya, P. Zimmerman et al., Fluoxetine-induced akathisia: Clinical and theoretical implications, J. Clin. Psychiatr. 50 (1989), 339-342.
19. P.G. Ney, C. Collins and C. Spensor, Double blind: Double talk or are there ways to do better research?, Med. Hypoth. 21 (1986), 119-129.
20. A.K. Shapiro and E. Shapiro, How blind is blind?, in: The Powerful Placebo, A.K. Shapiro and E. Shapiro, eds, The Johns Hopkins University Press, Baltimore, 1997, pp. 190-216.
21. M. Schou, Lithium in psychiatric therapy and prophylaxis, J. Psychiatr. Res. 6 (1968), 67-95.
22. S. Streufert and F.M. Gengo, Drugs and behavior, in: Effects of Drugs on Human Functioning. Progress in Basic Clinical Pharmacology, S. Streufert and F.M. Gengo, eds, Vol. 9, Karger, Basel, 1993, pp. 1-12.
23. D.T. Stuss and D.F. Benson, The Frontal Lobes, Raven Press, New York, 1986.
24. A. Summerfield, Behavioral toxicity: The psychology of pollution, J. Biolog. Sc. 10 (1978), 335-345.
25. M.H. Teicher, C. Glod and J.O. Cole, Antidepressant drugs and the emergence of suicidal tendencies, Drug Safety 8 (1993), 186-212.
26. N.B. Zinberg, Observations on the phenomenology of consciousness change, J. Psychedel. Drugs 8 (1976), 59-76.